STENTYS S.A. announced the pre-commercialization of Serpentis, its new Sirolimus-eluting stent with a bio-absorbable coating for routine procedures. Co-developed with a French industrial partner, Serpentis has received CE Marking and will be pre-commercialized by the end of the year to a selection of pilot centers across Europe. This new latest-generation active coronary Sirolimus drug-eluting stent is made of thin cobalt chromium mesh with a bio-absorbable polymer coating. With Serpentis, dedicated to routine procedures, and Xposition S, designed for more complex indications, STENTYS expands its product portfolio to cover all of its clients’ requirements. Furthermore, Xposition S has proven its efficacy in the SIZING study, of which the interim results were presented earlier this month at Transcatheter Cardiovascular Therapeutics (TCT) 2017, the international cardiac interventional conference in Denver, Colorado.